Home › NDC Lookup › RxCUI directory › RxCUI 153842

Glimepiride 3 MG Oral Tablet — RxCUI 153842

RxNorm drug concept · Semantic clinical drug
RxCUI 153842 Semantic clinical drug · SCD ● Current RxNorm concept 7 FDA products 13 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI153842
Official nameGlimepiride 3 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped7
Package NDCs mapped13
Reported Medicaid activity (SDUD)42,476 prescriptions · 37 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Glimepiride: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Glimepiride helps lower your blood sugar if you have type 2 diabetes. It works by prompting your pancreas to release more insulin, which helps move sugar out of your bloodstream an...
  • What exactly is glimepiride supposed to do for me?
  • Yes, timing with food really matters here. You should take glimepiride with your breakfast or your first main meal of the day — every day. Taking it with a meal helps reduce the ri...
  • When should I take it, and does it matter if I take it with food?
📖 Read our full Glimepiride guide →

🕸️ Concept Web — How Glimepiride 3 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Glimepiride 3 MG Oral Tablet RxCUI 153842

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Glimepiride 25789
  2. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Glimepiride Oral Tablet 372319
    • Glimepiride Oral Product 1157244
    • Glimepiride Pill 1157245
    • Oral Tablet 317541
    • Oral Product 1151131
    • Pill 1151133
  3. Clinical & branded drugs 1

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

    • Glimepiride 3 MG 380849

Showing up to 8 concepts per family — 8 of 8 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Glimepiride 3 MG SCDC · 380849
  • Glimepiride Oral Tablet SCDF · 372319
  • Glimepiride Oral Product SCDG · 1157244
  • Glimepiride Pill SCDG · 1157245

📦 FDA Products & Package NDCs

7 products · 13 package NDCs
13 package NDCs map to RxCUI 153842 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
42571-0100-01 100 TABLET in 1 BOTTLE (42571-100-01) Glimepiride Micro Labs Limited 2013-06-13
42571-0100-05 500 TABLET in 1 BOTTLE (42571-100-05) Glimepiride Micro Labs Limited 2013-06-13
42571-0101-01 100 TABLET in 1 BOTTLE (42571-101-01) Glimepiride Micro Labs Limited 2013-06-13
42571-0101-05 500 TABLET in 1 BOTTLE (42571-101-05) Glimepiride Micro Labs Limited 2013-06-13
42571-0102-01 100 TABLET in 1 BOTTLE (42571-102-01) Glimepiride Micro Labs Limited 2013-06-13
42571-0102-05 500 TABLET in 1 BOTTLE (42571-102-05) Glimepiride Micro Labs Limited 2013-06-13
42571-0103-01 100 TABLET in 1 BOTTLE (42571-103-01) Glimepiride Micro Labs Limited 2013-06-13
42571-0103-05 500 TABLET in 1 BOTTLE (42571-103-05) Glimepiride Micro Labs Limited 2013-06-13
42571-0104-01 100 TABLET in 1 BOTTLE (42571-104-01) Glimepiride Micro Labs Limited 2013-06-13
42571-0104-05 500 TABLET in 1 BOTTLE (42571-104-05) Glimepiride Micro Labs Limited 2013-06-13
42571-0105-01 100 TABLET in 1 BOTTLE (42571-105-01) Glimepiride Micro Labs Limited 2013-06-13
42571-0105-05 500 TABLET in 1 BOTTLE (42571-105-05) Glimepiride Micro Labs Limited 2013-06-13
72336-0641-01 100 TABLET in 1 BOTTLE (72336-641-01) Glimepiride 3 mg Lifsa Drugs LLC 2024-08-20
Observed labelers: Micro Labs Limited (12) · Lifsa Drugs LLC (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.